Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Compare

3,568 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IOVA Analyst Ratings

Moderate Buy

6 Buy

4 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Iovance

Biotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IOVA Stock 12 Month Forecast

Average Price Target

$9.30

▲(297.44%Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is $9.30 with a high forecast of $25.00 and a low forecast of $1.00. The average price target represents a 297.44% change from the last price of $2.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","26":"$26","6.5":"$6.5","19.5":"$19.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.5,13,19.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.74,3.5292307692307694,5.318461538461539,7.107692307692308,8.896923076923077,10.686153846153847,12.475384615384616,14.264615384615386,16.053846153846155,17.84307692307692,19.63230769230769,21.42153846153846,23.21076923076923,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.74,2.3215384615384616,2.903076923076923,3.4846153846153847,4.0661538461538465,4.647692307692308,5.229230769230769,5.810769230769231,6.392307692307693,6.9738461538461545,7.555384615384616,8.136923076923077,8.718461538461538,{"y":9.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.74,1.6830769230769231,1.626153846153846,1.5692307692307692,1.5123076923076924,1.4553846153846153,1.3984615384615384,1.3415384615384616,1.2846153846153845,1.2276923076923076,1.1707692307692308,1.1138461538461537,1.0569230769230769,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.88,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.06,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$9.30

Lowest Price Target$1.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

-14.53%

Downside

Reiterated

07/16/25

Iovance Biotherapeutics' overall stock score reflects its current financial challenges and technical indicators. While there is significant potential for growth from recent product launches and market expansion, ongoing operational inefficiencies and a lack of profitability weigh heavily on the score. The recent CFO appointment and shareholder support are positive, but the valuation remains a concern.

Andrea NewkirkGoldman Sachs

Goldman Sachs

Sell

-57.26%

Downside

Downgraded

07/15/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA) and Eli Lilly & Co (NYSE: LLY)

Peter LawsonBarclays

Barclays

Buy

70.94%

Upside

Reiterated

07/15/25

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)

Reni BenjaminCitizens JMP

Citizens JMP

―

Hold

―

Reiterated

07/15/25

Citizens JMP Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$20

Buy

754.70%

Upside

Reiterated

07/15/25

H.C. Wainwright sees 'impressive' commercial data for Iovance's AmtagviH.C. Wainwright sees 'impressive' commercial data for Iovance's Amtagvi

Tyler Van BurenTD Cowen

TD Cowen

Buy

113.68%

Upside

Reiterated

06/02/25

Iovance Biotherapeutics (IOVA) Receives a Buy from TD Cowen

Yanan ZhuWells Fargo

Wells Fargo

$18

Buy

669.23%

Upside

Reiterated

06/01/25

Promising Developments and Strategic Advantages Drive Buy Rating for Iovance Biotherapeutics

David DaiUBS

UBS

Hold

-14.53%

Downside

Downgraded

05/16/25

Cautious Outlook for Iovance Biotherapeutics Amid Amtagvi Sales Challenges

Asthika GoonewardeneTruist Financial

Truist Financial

Hold

113.68%

Upside

Downgraded

05/12/25

Iovance Biotherapeutics downgraded to Hold from Buy at TruistIovance Biotherapeutics downgraded to Hold from Buy at Truist

Geulah LivshitsChardan Capital

Chardan Capital

$30→$25

Buy

968.38%

Upside

Reiterated

05/09/25

Iovance Biotherapeutics price target lowered to $25 from $30 at ChardanIovance Biotherapeutics price target lowered to $25 from $30 at Chardan

Colleen M. KusyRobert W. Baird

Robert W. Baird

$20→$3

Hold

28.21%

Upside

Downgraded

05/09/25

Baird downgrades Iovanace Biotherapeutics (IOVA) to NeutralBaird analyst Colleen Kusy downgraded Iovanace Biotherapeutics (NASDAQ: IOVA) from Outperform to Neutral with a price target of $3.00 (from $20.00).

Salim SyedMizuho Securities

Mizuho Securities

$30→$10

Buy

327.35%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), GH Research (NASDAQ: GHRS) and NewAmsterdam Pharma Company (NASDAQ: NAMS)

Kelsey GoodwinGuggenheim

Guggenheim

―

Hold

―

Reiterated

04/01/25

Benjamin BurnettStifel Nicolaus

Stifel Nicolaus

$18

Buy

669.23%

Upside

Reiterated

03/17/25

Iovance Biotherapeutics (IOVA) Receives a Buy from Stifel Nicolaus

Michael YeeJefferies

Jefferies

$23→$18

Buy

669.23%

Upside

Reiterated

03/13/25

Iovanace Biotherapeutics (IOVA) PT Lowered to $18 at JefferiesJefferies analyst Michael Yee lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $18.00 (from $23.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

-14.53%

Downside

Reiterated

07/16/25

Andrea NewkirkGoldman Sachs

Goldman Sachs

Sell

-57.26%

Downside

Downgraded

07/15/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA) and Eli Lilly & Co (NYSE: LLY)

Peter LawsonBarclays

Barclays

Buy

70.94%

Upside

Reiterated

07/15/25

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)

Reni BenjaminCitizens JMP

Citizens JMP

―

Hold

―

Reiterated

07/15/25

Citizens JMP Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$20

Buy

754.70%

Upside

Reiterated

07/15/25

H.C. Wainwright sees 'impressive' commercial data for Iovance's AmtagviH.C. Wainwright sees 'impressive' commercial data for Iovance's Amtagvi

Tyler Van BurenTD Cowen

TD Cowen

Buy

113.68%

Upside

Reiterated

06/02/25

Iovance Biotherapeutics (IOVA) Receives a Buy from TD Cowen

Yanan ZhuWells Fargo

Wells Fargo

$18

Buy

669.23%

Upside

Reiterated

06/01/25

Promising Developments and Strategic Advantages Drive Buy Rating for Iovance Biotherapeutics

David DaiUBS

UBS

Hold

-14.53%

Downside

Downgraded

05/16/25

Cautious Outlook for Iovance Biotherapeutics Amid Amtagvi Sales Challenges

Asthika GoonewardeneTruist Financial

Truist Financial

Hold

113.68%

Upside

Downgraded

05/12/25

Iovance Biotherapeutics downgraded to Hold from Buy at TruistIovance Biotherapeutics downgraded to Hold from Buy at Truist

Geulah LivshitsChardan Capital

Chardan Capital

$30→$25

Buy

968.38%

Upside

Reiterated

05/09/25

Iovance Biotherapeutics price target lowered to $25 from $30 at ChardanIovance Biotherapeutics price target lowered to $25 from $30 at Chardan

Colleen M. KusyRobert W. Baird

Robert W. Baird

$20→$3

Hold

28.21%

Upside

Downgraded

05/09/25

Salim SyedMizuho Securities

Mizuho Securities

$30→$10

Buy

327.35%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), GH Research (NASDAQ: GHRS) and NewAmsterdam Pharma Company (NASDAQ: NAMS)

Kelsey GoodwinGuggenheim

Guggenheim

―

Hold

―

Reiterated

04/01/25

Benjamin BurnettStifel Nicolaus

Stifel Nicolaus

$18

Buy

669.23%

Upside

Reiterated

03/17/25

Iovance Biotherapeutics (IOVA) Receives a Buy from Stifel Nicolaus

Michael YeeJefferies

Jefferies

$23→$18

Buy

669.23%

Upside

Reiterated

03/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Iovance Biotherapeutics

1 Month

xxx

Success Rate

14/32 ratings generated profit

Average Return

+2.63%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 43.75% of your transactions generating a profit, with an average return of +2.63% per trade.

3 Months

xxx

Success Rate

9/15 ratings generated profit

Average Return

+12.11%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +12.11% per trade.

1 Year

Geulah LivshitsChardan Capital

Success Rate

14/32 ratings generated profit

Average Return

+8.58%

reiterated a buy rating 2 months ago

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +8.58% per trade.

2 Years

xxx

Success Rate

7/32 ratings generated profit

Average Return

-33.92%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 21.88% of your transactions generating a profit, with an average return of -33.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IOVA Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IOVA has received 14 Buy Ratings, 10 Hold Ratings, and 1 Sell Ratings. IOVA average Analyst price target in the past 3 months is 9.30.

Each month's total comprises the sum of three months' worth of ratings.

IOVA Financial Forecast

IOVA Earnings Forecast

Next quarter’s earnings estimate for IOVA is -$0.28 with a range of -$0.34 to -$0.25. The previous quarter’s EPS was -$0.36. IOVA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year IOVA has Preformed in-line its overall industry.

IOVA Sales Forecast

Next quarter’s sales forecast for IOVA is $67.10M with a range of $55.16M to $75.90M. The previous quarter’s sales results were $49.32M. IOVA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year IOVA has Preformed in-line its overall industry.

IOVA Stock Forecast FAQ

What is IOVA’s average 12-month price target, according to analysts?

Based on analyst ratings, Iovance Biotherapeutics Inc’s 12-month average price target is 9.30.

What is IOVA’s upside potential, based on the analysts’ average price target?

Iovance Biotherapeutics Inc has 297.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IOVA a Buy, Sell or Hold?

Iovance Biotherapeutics Inc has a consensus rating of Moderate Buy which is based on 6 buy ratings, 4 hold ratings and 1 sell ratings.

What is Iovance Biotherapeutics Inc’s price target?

The average price target for Iovance Biotherapeutics Inc is 9.30. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $1.00. The average price target represents 297.44% Increase from the current price of $2.34.

What do analysts say about Iovance Biotherapeutics Inc?

Iovance Biotherapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of IOVA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

IOVA Analyst Ratings

IOVA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Iovance Biotherapeutics

IOVA Analyst Recommendation Trends

IOVA Financial Forecast

IOVA Earnings Forecast

IOVA Sales Forecast

IOVA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts